ArticleAACE endocrinology and diabetes
Water-Clear Cell Parathyroid Adenoma Causing Delayed Diagnosis and Negative Imaging in Primary Hyperparathyroidism.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for the Special Issue Entitled "Novel Aspects of Endocrine Care: From Patient-Centered Management of Endocrine Diseases to Guidelines Standards".Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid water-clear cell adenomas are rare causes of primary hyperparathyroidism, with fewer than 30 cases reported in the medical literature worldwide. Over the years, these tumors have been associated with delayed diagnosis and treatment, as well as challenges in the management of hyperparathyroidism. We report the case of a 36-year-old female with a medical history of stage IV chronic kidney disease who presented with a large parathyroid adenoma composed predominantly of clear cells. Her diagnosis was delayed due to negative preoperative imaging findings despite markedly elevated parathyroid hormone levels of 1,100 pg/mL (reference range: 10-65 pg/mL) and serum calcium of 10.9 mg/dL (reference range: 8.0-10.5 mg/dL) while on cinacalcet therapy. A sestamibi parathyroid scan with SPECT/CT failed to localize the adenoma. However, given that the patient met multiple criteria for surgery-including young age, distal forearm osteoporosis, and a creatinine clearance below 60 mL/min-she was referred for parathyroidectomy. Intraoperatively, a large parathyroid adenoma was identified, which had not been detected on preoperative imaging. Histopathologic examination revealed a predominance of clear cells with fewer than 10% oxyphil cells and fewer than 5% chief cells, consistent with the water-clear cell subtype of parathyroid adenoma. Sestamibi imaging depends on delayed radiotracer washout from mitochondria-rich oxyphil cells; therefore, the high false-negative rate for this subtype may be attributed to its glycogen-rich, mitochondria-poor cytoplasm, which allows rapid tracer washout. Recognizing these tumors is crucial for the early diagnosis and appropriate management of primary hyperparathyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.